- Amgen is set to release its Q2 2026 earnings, with analysts projecting a 2.9% revenue increase despite a 7% decline in earnings.
- The biotechnology company shows a positive Earnings ESP and strong performance from key drugs like Repatha, Tezspire, and Evenity, having surpassed analyst expectations by 8.88% last quarter.
- Investors are monitoring the MariTide obesity drug candidate and biosimilar sales, alongside valuation metrics like a Price-to-Earnings (P/E) ratio of 26.47 and a Debt-to-Equity ratio of 6.24.
Amgen (NASDAQ: AMGN) is a leading biotechnology company that discovers, develops, and delivers innovative human medicines. The company operates in a competitive landscape with other major pharmaceutical firms like J&J, Biogen, and Bristol Myers, many of which have recently reported strong quarterly results and raised their financial outlooks for the current period.
Amgen is scheduled to release its second-quarter earnings report on August 4, 2026. Wall Street analysts have set consensus estimates for the quarter, projecting earnings of $5.60 per share on revenues of approximately $9.45 billion. This represents a 7% year-over-year decline in earnings but a 2.9% increase in revenue.
The company enters the quarter with a positive Earnings ESP (Earnings Surprise Prediction), as highlighted by Zacks Investment Research. This outlook is supported by strong volume growth from key drugs like Repatha, Tezspire, and Evenity. In the previous quarter, Amgen's earnings surpassed analyst expectations by a notable 8.88%, continuing a positive trend.
Despite the expected sales growth, performance may be partly offset by pricing pressures and other market factors. Investors will also be watching for updates on the company's MariTide obesity drug candidate and sales trends for its biosimilar products, which are near-identical copies of other approved biologic medicines.
From a valuation standpoint, Amgen has a Price-to-Earnings (P/E) ratio of 26.47, which indicates the price investors pay for each dollar of company earnings. The company's financial structure includes a Debt-to-Equity ratio of 6.24, a measure that compares a company's total debt to its shareholder equity.